Exosomes, a key element of ExoTherapy, are derived from stem cells in bio-production processes. The Technion-developed process suggests that shear stress stimulation of stem cells during Three-Dimensional (3D) exosome production yields both increased secretion of exosomes and enhanced exosome potency. NurExone carried out a pilot study of the shear stress

The Company will be participating in the upcoming 2022 Bio-Europe Conference (“Bio-Europe”) in Leipzig, Germany, which commences on October 24th and ends on October 26th. Bio-Europe is regarded as one of Europe’s largest gathering of professionals in the biopharma industry. Over 4000 attendees and more than 2200 companies from around

Calgary, Alberta and Oxford, United Kingdom–(Newsfile Corp. – October 12, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company’s wholly-owned subsidiary, NurExone Biologic Ltd., signed

Calgary, Alberta–(Newsfile Corp. – October 4, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company’s lab showing the effectiveness of the

NurExone Announces Additional Securities for Debt Settlemen Read More

Under the Letter of Intent, NurExone will explore collaborations with denovoMATRIX to use its advanced screenMATRIX platform to develop specialized coatings for NurExone’s cell carriers for exosome production in order to optimize the manufacturing processes of the non-invasive NurExone’s ExoTherapy. The primary aim of the collaboration is to develop a

Calgary, Alberta–(Newsfile Corp. – September 1, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares of the Company at a deemed

Calgary, Alberta–(Newsfile Corp. – August 25, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients suffering from traumatic spinal cord injuries, released a business update and reported financial results for the quarter ended June 30, 2022. 

https://www.newsfilecorp.com/release/133194/James-Richardson-the-Former-CEO-of-EnerSpar-Updates-Shareholders-After-the-Completion-of-RTO-with-NurExone-Biologic

Newsfile Corp. July 19, 2022·5 min read Calgary, Alberta–(Newsfile Corp. – July 19, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System (“CNS”) indications, announced the signing of a Material